Addressing the immunogenicity of the cargo and of the targeting antibodies with a focus on deimmunized bacterial toxins and on antibody-targeted human effector proteins

Yehudit Grinberg, Itai Benhar*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Third-generation immunotoxins are composed of a human, or humanized, targeting moiety, usually a monoclonal antibody or an antibody fragment, and a non-human effector molecule. Due to the non-human origin of the cytotoxic domain, these molecules stimulate potent anti-drug immune responses, which limit treatment options. Efforts are made to deimmunize such immunotoxins or to combine treatment with immunosuppression. An alternative approach is using the so-called "human cytotoxic fusion proteins", in which antibodies are used to target human effector proteins. Here, we present three relevant approaches for reducing the immunogenicity of antibody-targeted protein therapeutics: (1) reducing the immunogenicity of the bacterial toxin, (2) fusing human cytokines to antibodies to generate immunocytokines and (3) addressing the immunogenicity of the targeting antibodies.

Original languageEnglish
Article number28
JournalBiomedicines
Volume5
Issue number2
DOIs
StatePublished - 1 Jun 2017

Keywords

  • Deimmunization
  • Immunocytokines
  • Immunotoxins

Fingerprint

Dive into the research topics of 'Addressing the immunogenicity of the cargo and of the targeting antibodies with a focus on deimmunized bacterial toxins and on antibody-targeted human effector proteins'. Together they form a unique fingerprint.

Cite this